Aging Clinical Trial
— STEP-agingOfficial title:
Effect of Fecal Microbiota Transplantation on Aging and the Underlying Mechanism of Gut Microbiome Restoration: a Randomized Clinical Trial
A severe public health issue facing global population is aging. Increasing preclinical and clinical data indicate the contribution of gut microbiome on aging and aging-related diseases such as cardiovascular disease, Alzheimer Disease, and diabetes. Interventions on microbiota are developed including prebiotics, probiotics, and fecal microbial transplantation (FMT). FMT via oral capsules also advances in recent with limited safety concerns compared with invasive routes. A hypothesis is thus raised that gut microbiome intervention via oral FMT can be a potential safe approach to encourage healthy aging, with multiple aspects evaluated for clinical phenotype of frailty, anthropometric measurement, cognitive function, cardiovascular aging, physical function, living activity, hippocampal volume, telomere length, cognitive biomarkers, inflammatory biomarkers, altered microbial composition and metabolites.
Status | Not yet recruiting |
Enrollment | 210 |
Est. completion date | December 31, 2027 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 70 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Age 70-85 years. 2. Patients with informed consent after thorough explanation. Exclusion Criteria: 1. Participants of other clinical trials; 2. Antibiotics or probiotics usage within last 4 weeks; 3. Severe hepatic or renal diseases ((ALT >3 times the upper limit of normal value, or end stage renal disease on dialysis or eGFR <30 mL/min/1.73 m2, or serum creatinine >2.5 mg/dl [>221 µmol/L]); 4. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack [TIA]); 5. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months; 6. NYHA class III-IV heart failure; Hospitalization for chronic heart failure exacerbation within last 6 months; 7. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period; 8. Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Rheumatic heart disease; Congenital heart disease; 9. History of dementia, Parkinson's disease, intracranial infection, intracranial tumor, schizophrenia, anxiety, depression; 10. History of neurosurgical operation; 11. History of gastrointestinal tumor, gastrointestinal surgery, inflammatory bowel disease; Hospitalization for peptic ulcer disease exacerbation within last 6 months or anticipated hospitalization for peptic ulcer disease the next 6 months; 12. Hypertension with uncontrolled blood pressure =180/110mmHg; 13. Diabetes Mellitus with uncontrolled fasting glucose level =200mg/dl (11.1mmol/L), or HbA1C>8%; 14. Addicted to alcohol; Use of medication influencing cognitive function(i.e., antihistamine, antipsychotic); 15. General anesthesia within last 3 months; 16. Other severe diseases influencing the entry or survival of participants, such as malignant tumor or acquired immune deficiency syndrome, life expectancy <1 year; 17. Impaired verbal communication who are incapable of providing their own informed consent, or incapable of self-care; 18. Special diet influencing microbiota (i.e. vegetarian); 19. Other conditions inappropriate for recruitment according to the investigators. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Chinese Academy of Medical Sciences, Fuwai Hospital |
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. — View Citation
Ghosh TS, Rampelli S, Jeffery IB, Santoro A, Neto M, Capri M, Giampieri E, Jennings A, Candela M, Turroni S, Zoetendal EG, Hermes GDA, Elodie C, Meunier N, Brugere CM, Pujos-Guillot E, Berendsen AM, De Groot LCPGM, Feskins EJM, Kaluza J, Pietruszka B, Bie — View Citation
Kundu P, Lee HU, Garcia-Perez I, Tay EXY, Kim H, Faylon LE, Martin KA, Purbojati R, Drautz-Moses DI, Ghosh S, Nicholson JK, Schuster S, Holmes E, Pettersson S. Neurogenesis and prolongevity signaling in young germ-free mice transplanted with the gut micro — View Citation
Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore DJ, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Goldenberg SD, Williams HRT. The use of faecal microbiota transplant as treatment for recurrent or ref — View Citation
Ng TP, Feng L, Nyunt MS, Feng L, Niti M, Tan BY, Chan G, Khoo SA, Chan SM, Yap P, Yap KB. Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial. Am J Med. 2015 Nov;128(11):12 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of participants with reduced frailty score at week 96 follow-up | Frailty score via CHS criteria of five frailty components, compared with baseline | week 96 | |
Secondary | Proportion of participants with reduced frailty score at week 12 follow-up | Frailty score via CHS criteria of five frailty components, compared with baseline | week 12 | |
Secondary | Proportion of participants with reduced frailty score at week 24 follow-up | Frailty score via CHS criteria of five frailty components, compared with baseline | week 24 | |
Secondary | Proportion of participants with reduced frailty score at week 48 follow-up | Frailty score via CHS criteria of five frailty components, compared with baseline | week 48 | |
Secondary | Proportion of participants with reduced frailty score at week 72 follow-up | Frailty score via CHS criteria of five frailty components, compared with baseline | week 72 | |
Secondary | Change from baseline in Frailty score | Frailty score via CHS criteria of five frailty components, ranging from 0 to 5, with higher score indicating worse outcome | week 12, week 24, week 48, week 72, week 96, compared with baseline | |
Secondary | Change from baseline in telomere length | Change from baseline in telomere length | week 48, week 96 | |
Secondary | Change from baseline in Cognitive assessment via Mini Mental State Examination(MMSE) | MMSE (Mini Mental State Examination) ranging from 0 to 30, with lower score indicating worse outcome | week 24, week 48, week 72, week 96, compared with baseline | |
Secondary | Change from baseline in Cognitive assessment via Montreal Cognitive Assessment(MoCA) | MoCA (Montreal Cognitive Assessment) ranging from 0 to 30, with lower score indicating worse outcome | week 24, week 48, week 72, week 96, compared with baseline | |
Secondary | Change from baseline in Hippocampal volumes | Hippocampal volumes evaluated by Magnet Resonance Imaging | week 48, week 96 | |
Secondary | Change from baseline in cognitive biomarkers | plasma levels of cognitive biomarkers for BDNF?tau?Aß-40?Aß42 | week 12, week 24, week 48, week 72, week 96 | |
Secondary | Change from baseline in inflammatory biomarkers | plasma levels of inflammatory biomarkers for hs-C-reactive protein (hs-CRP)? interleukin 6(IL-6)?interleukin 1 ß(IL-1 ß) ?interleukin10 (IL-10)?tumor necrosis factor a(TNF-a) | week 12, week 24, week 48, week 72, week 96 | |
Secondary | Change from baseline in Intestinal Microbiota Composition Pre- and Post-intervention via Metagenomic Analysis | Change in Intestinal Microbiota Composition Pre- and Post-intervention (FMT or Placebo) via Metagenomic Analysis, stratified by:
Randomisation Change in Office SBP |
week 12, week 24, week 48, week 72, week 96 | |
Secondary | Change from baseline in Intestinal Microbiota Function assessed by KEGG Orthology (KO) Pre- and Post-intervention via Metagenomic Analysis | Change in Intestinal Microbiota Function assessed by KEGG Orthology (KO) Pre- and Post-intervention (FMT or Placebo) via Metagenomic Analysis, stratified by:
Randomisation Change in Office SBP |
week 12, week 24, week 48, week 72, week 96 | |
Secondary | Change from baseline in Plasma Metabolite Composition Pre- and Post-intervention via Metabolomic Analysis | Change in Plasma Metabolite Composition Pre-and Post-intervention (FMT or Placebo) via Metabolomic Analysis | week 12, week 24, week 48, week 72, week 96 | |
Secondary | Change from baseline in Ankle-Brachial Blood Pressure Index(ABI) | Change for ABI as an objective measurement of arterial insufficiency based on the ratio of ankle systolic pressure to brachial systolic pressure. | week 48, week 96 | |
Secondary | Change from baseline in Pulse wave velocity(PWV) | Change for Pulse wave velocity(PWV) | week 48, week 96 | |
Secondary | Number of Participants with Adverse Events (AEs) as a Measure of Safety | Number of Participants with Adverse Events (AEs) as a Measure of Safety | week 12, week 24, week 48, week 72, week 96 | |
Secondary | Change from baseline in Body Mass Index (BMI) | Change for Body Mass Index | week 4, week 8, week 12, week 24, week 48, week 72, week 96 | |
Secondary | Change from baseline in office SBP | change for office systolic blood pressure(SBP) | week 4, week 8, week 12, week 24, week 48, week 72, week 96 | |
Secondary | Change from baseline in office DBP | change for office diastolic blood pressure(DBP) | week 4, week 8, week 12, week 24, week 48, week 72, week 96 | |
Secondary | Change from baseline in Blood Lipid Level | Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol) | week 12, week 24, week 48, week 96 | |
Secondary | Change from baseline in blood fasting glucose level | Change for blood fasting glucose level | week 12, week 24, week 48, week 96 | |
Secondary | Change from baseline in blood HbA1c level | Change for blood glycosylated hemoglobin, type A1C (HbA1c) level | week 12, week 24, week 48, week 96 | |
Secondary | Change from baseline in physical function assessment via 6MWT | 6-minute walking test(6MWT) | week 12, week 24, week 48, week 72, week 96 | |
Secondary | Change from baseline in daily function assessment via Activity of Daily Living (ADL) | Activity of Daily Living (ADL) ranging from 0 to 100, with lower score indicating worse outcome | week 12, week 24, week 48, week 72, week 96 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Completed |
NCT05293730 -
Trial of the Impact of the Electronic Frailty Integrated With Social Needs
|
N/A | |
Recruiting |
NCT03932162 -
Gene Expression Changes In Young and Geriatric Skin
|
Early Phase 1 | |
Completed |
NCT04064528 -
Effects of Age on Amino Acid Delivery to Tendon
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT06029920 -
Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT05543980 -
Leg Heat Therapy in Elderly Individuals
|
Phase 2 | |
Recruiting |
NCT05566938 -
Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly
|
N/A | |
Completed |
NCT04894929 -
Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement
|
N/A | |
Not yet recruiting |
NCT06071130 -
Emotion, Aging, and Decision Making
|
N/A | |
Enrolling by invitation |
NCT04641663 -
Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST)
|
N/A | |
Completed |
NCT04088006 -
The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity
|
N/A | |
Completed |
NCT03695081 -
Patient Pathway Pharmacist - Optimal Drug-related Care
|
N/A | |
Recruiting |
NCT05424263 -
Acetate and Age-associated Arterial Dysfunction
|
Phase 2 | |
Completed |
NCT05601713 -
Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling
|
N/A | |
Completed |
NCT04551339 -
Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19
|
N/A | |
Recruiting |
NCT04997577 -
Speech Perception and High Cognitive Demand
|
N/A | |
Completed |
NCT05922475 -
Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training
|
N/A | |
Completed |
NCT04015479 -
Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults
|
N/A |